Den kumulative sandsynlighed for udvikling af genotypisk entecavir- resistens efter 1, 2, 3, 4 og 5 års behandling i undersøgelser af lamivudin- resistens var henholdsvis 6%, 15%, 36%, 47% og 51%.
The cumulative probability of emerging genotypic entecavir resistance after 1, 2, 3, 4 and 5 years treatment in the lamivudine-refractory studies was 6%, 15%, 36%, 47% and 51%, respectively.